OptiBiotix Health PLC Agreement with global corporate for SweetBiotix® (5010S)
June 26 2018 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5010S
OptiBiotix Health PLC
26 June 2018
26 June 2018
OptiBiotix Health plc
("OptiBiotix" or the Company")
Agreement with global corporate for SweetBiotix(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol and
diabetes, announces that it has entered into an agreement with a
global corporate for its SweetBiotix(R) low calorie sweet fibres.
The agreement sets out the terms and grants exclusivity, for a
period of six months, to negotiate a license agreement for the
scale up, manufacture and distribution of its SweetBiotix(R) low
calorie sweet fibres. OptiBiotix will receive monthly payments
during this exclusivity period amounting to a six figure sum.
OptiBiotix has previously announced (RNS: 27 March 2018) that it
has carried out five successful human taste studies on a range of
products developed from its SweetBiotix(R) development programmes.
This has created interest from a number of corporates with
expertise in the manufacture and commercialisation of speciality
ingredients and/or consumer products. This agreement reflects the
materialisation of interest from one of these companies in scaling
up, manufacturing and distributing SweetBiotix(R) from one of its
development programmes.
The company is a global supplier of nutritional and agricultural
products to companies around the world with an annual turnover
exceeding $100bn. The organisation requires its identity and the
terms of the agreement to remain confidential and no further
details can be disclosed. A further announcement will be made in
due course.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce the signing of this agreement for SweetBiotix(R) with one
of the world's largest suppliers of nutritional and agricultural
products. This is the second agreement with global partners for
products created from our SweetBiotix(R) development programmes.
This is part of a strategy of working with global partners to
support scale up, manufacture and commercialisation of a range of
SweetBiotix(R) products in well-known consumer brands. With
international concerns over the balance of sugars and fibres in
consumer diets rising, OptiBiotix's is at the forefront of product
development in this area of growing industry and commercial
interest."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBXGDLBUDBGIU
(END) Dow Jones Newswires
June 26, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024